Actively Recruiting

Age: 18Years +
All Genders
ID03894917

Characterizing Disease Biology, Treatment Patterns and Toxicity in Older Adults With Advanced Hepatocellular Carcinoma

Led by The University of Texas Health Science Center at San Antonio · Updated on 2026-01-08

84

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are conducting an observational study involving 84 participants newly diagnosed with unresectable, advanced hepatocellular carcinoma (HCC). The study focuses on understanding disease characteristics, treatment patterns, and toxicity, especially in older adults aged 65 and above, by using geriatric assessment tools and collecting markers related to aging and treatment side effects. Participants aged 65 years or older will undergo Comprehensive Geriatric Assessment before receiving their standard interventional treatment. The study groups include those 65 years and older and those younger than 65. Observations include treatment toxicities and cellular aging changes related to treatment outcomes. Participants will be monitored at several time points including screening, and months 1, 2, 4, 6, 8, 10, and 12. Researchers will collect data on disease progression, treatment patterns, and adverse events. This monitoring aims to help develop personalized treatment plans for older adults based on the study findings. The total participation lasts up to 12 months with regular assessments.

CONDITIONS

Brief Title

Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically or radiographically (CT or MRI) confirmed newly diagnosed hepatocellular carcinoma
  • Age 18 years and older
  • Patients with advanced, unresectable HCC as determined by the treating physician
Not Eligible

You will not qualify if you...

  • Patients with resectable HCC who are still candidates for locoregional therapy
  • Patients receiving prior systemic or locoregional therapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - 12 months

Participants undergo assessments including Comprehensive Geriatric Assessment and observation of disease characteristics, treatment patterns, and toxicities over time.

Visits at Month 1, Month 2, Month 4, Month 6, Month 8, Month 10, and Month 12

Trial Site Locations

Total: 1 location

1

Mays Cancer Center

San Antonio, Texas, United States, 78229

Actively Recruiting

Loading map...

Research Team

M

Maggie Tomasini, MPH

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

Randomized Study of Therasphere 90-Yittrium Transarterial Ra...

Carcinoma, Hepatocellular

Actively Recruiting

1 location

Phase II Study Evaluating HLX43 (Anti-PD-L1 ADC) in Patients...

Carcinoma, Hepatocellular

Actively Recruiting

1 location

A Phase 2 Open-Label Study of Irpagratinib with Atezolizumab...

Carcinoma, Hepatocellular

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here